ARTICLE | Clinical News
OraVescent fentanyl regulatory update
September 12, 2005 7:00 AM UTC
CEPH submitted an NDA to FDA for OraVescent fentanyl buccal tablet to manage breakthrough cancer pain in patients who already are receiving and are tolerant to opioid therapy. The submission was based...